This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Other. Active years: 2015-2017.
Company Filing History:
1 out of 181 
1 out of 911 
1 out of 834,411 Years Active: 2015-2017
Title: Ron Eliashar: Innovator in Immune-Related Disorder Treatments
Introduction
Ron Eliashar is a notable inventor based in Har-Adar, Israel. He has made significant contributions to the field of medical research, particularly in the treatment of immune-related disorders. With a total of 2 patents, Eliashar's work focuses on innovative solutions that address various health challenges.
Latest Patents
Eliashar's latest patents include groundbreaking methods and compositions utilizing desferrioxamine-metal complexes. These inventions specifically involve Zinc-desferrioxamine (Zn-DFO) and gallium-desferrioxamine (Ga-DFO) complexes. The primary aim of these inventions is to prevent, treat, ameliorate, or inhibit immune-related disorders. This includes skin-related inflammatory disorders such as psoriasis, inflammatory respiratory conditions like asthma, and autoimmune diseases such as diabetes.
Career Highlights
Throughout his career, Ron Eliashar has worked with various organizations, including Hadasit Medical Research Services and Development Ltd. His innovative approach and dedication to research have positioned him as a key figure in the medical research community.
Collaborations
Eliashar has collaborated with notable individuals in his field, including Mordechai Chevion and Vladimir Vinokur. These partnerships have contributed to the advancement of his research and the development of his patents.
Conclusion
Ron Eliashar's contributions to the treatment of immune-related disorders through his innovative patents highlight his commitment to improving health outcomes. His work continues to inspire advancements in medical research and treatment methodologies.